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Peripheral Arterial Disease affects Kinematics during Walking

2
3

ABSTRACT

4

Objective: Claudication is the most common manifestation of peripheral arterial disease

5

(PAD) producing significant ambulatory compromise. The purpose of this study was to use

6

advanced biomechanical analysis to characterize the kinematic ambulatory pattern of claudicating

7

patients. We hypothesized that compared to control subjects, claudicating patients have altered

8

kinematic gait patterns that can be fully characterized utilizing advanced biomechanical analysis.

9

Methods: The study examined fourteen PAD patients (age: 58 +/- 3.4 years; weight: 80.99

10

+/- 15.64 kg) with clinically diagnosed femoro-popliteal occlusive disease (Ankle Brachial Index

11

(ABI): 0.56 +/- 0.03, range 0.45-0.65) and five healthy controls (age: 53 +/- 3.4 years; weight:

12

87.38 +/- 12.75 kg; ABI  1). .inematic parameters (hip, knee and ankle joint angles in the sagittal

13

plane) were evaluated during gait in patients before and after the onset of claudication pain and

14

compared to healthy controls. Joint angles were calculated during stance time. Dependent variables

15

were assessed (maximum and minimum flexion and extension angles and ranges of motion) and

16

mean ensemble curves were generated. Time to occurrence of the discrete variables was also

17

identified.

18

Results: Significantly greater ankle plantar flexion in early stance and ankle range of motion

19

during stance was observed in PAD patients (P<0.05). Time to maximum ankle plantarflexion was

20

shorter and time to maximum ankle dorsiflexion was longer in PAD patients (P<0.05). These

21

differences were noted when comparing PAD patients prior to and after the onset of claudication

22

with healthy controls. The analysis of the kinematic parameters of the knee and the hip joints

23

revealed no significant differences between PAD patients and controls.

24

Conclusion: PAD patients with claudication demonstrate significant gait alterations in the

25

ankle joint that are present prior to the onset of claudication pain. In contrast, the joint motion of the

26

hip and knee did not differ in PAD patients when compared to controls. Further research is needed

2
1

to verify our findings and assess the impact of more proximal disease in PAD patients as well as the

2

effect of revascularization on joint kinematics.

3

KEYWORDS: Claudication, Gait, Kinematics, Peripheral Arterial Disease, Biomechanics
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INTRODUCTION
Peripheral arterial disease (PAD) of the lower extremities is a manifestation of
(1,2)

3

atherosclerosis, affecting 20%-30% of older patients in general medical practices

and up to 12

4

million people in the United States population.(3,4) Intermittent claudication (IC), defined as lower

5

extremity pain that causes the patient to stop walking and resolves within few minutes of rest, is

6

considered the classic symptom of PAD. Recently IC has been identified as an ambulatory disorder.

7

This is supported by studies demonstrating PAD patients to have lower daily physical activity(5),

8

reduced strength in lower extremities(6), worse self-perceived ambulatory function(7), lower health

9

related quality of life(8), impaired balance and higher prevalence of falling(9).

10

The characterization of the gait of patients with IC until recently has been limited to the

11

measurement of simple temporal and spatial parameters of the patients’ walking performance. Such

12

evaluations have documented that PAD patients have decreased step length, cadence, walking speed

13

and increased stance time(10,11)These measures suggest the presence of ambulation abnormalities in

14

claudicating patients; however they provide limited insight into the specific site and mechanisms

15

producing the abnormal gait.

16

Biomechanical analysis, in contrast to the previously used rudimentary measurements

17

mentioned above, represents an important diagnostic tool with the ability to provide detailed and

18

accurate quantitative gait analysis. Furthermore, biomechanical evaluation is common practice is

19

several other medical domains (i.e. orthopedics, pediatrics, neurology, etc ) and has been useful in

20

both research and clinical settings for directing treatment in varying pathologies as well as in

21

outcome evaluation of the results of such treatments(12-15). In contrast to the progress made in other

22

fields where advanced biomechanics has been implemented, very little has been done to provide an

23

in depth analysis of the underlying biomechanical gait abnormalities produced by PAD(16,17).

24

The purpose of the current study was to determine the gait of patients with symptomatic

25

PAD before and after the onset of claudication utilizing advanced biomechanical analysis. We

26

hypothesized that the lower extremities of PAD patients have altered joint displacement compared

4
1

to control subjects both before and after the onset of claudication, and that biomechanical kinematic

2

analysis represents a diagnostic tool with appropriate sensitivity to detect subtle differences in a

3

subject’s gait. The current kinematic study, which focuses on the lower extremity joints’ angular

4

displacement independently of the generating forces, complements the kinetic analysis previously

5

described by our group

6

on the ground. Our work seeks to further enhance our understanding of the abnormal gait in

7

subjects with PAD, thus providing the foundation for the development of new rehabilitation

8

strategies and the quantification of treatment outcomes for patients with symptomatic PAD.

(18)

which evaluated the forces exerted by the subjects weight-bearing limb

9
10

METHODS

11

Subjects

12

Institutional Review Board approval was obtained prior to initiation of the study and all

13

subjects provided informed consent. Patients with clinically diagnosed PAD presenting with classic

14

symptomatic claudication were recruited from our vascular surgery clinics. Selected patients were

15

free of any associated co-morbidities limiting or altering their gait. Specifically, subjects were

16

excluded if they had recent myocardial infarction or ambulation-limiting heart failure, angina or

17

pulmonary disease. Additionally, subjects were excluded if they had gait altering neurological or

18

musculoskeletal disease such as paresis, sciatica, arthritis, diabetic neuropathy or arthropathy.

19

History and physical examination of the subjects evaluated was performed by board certified

20

vascular surgeons (JJ, IP). Lower extremity arterial disease was verified by classic clinical

21

symptoms confirmed utilizing noninvasive testing (ankle-brachial indexes < 0.9) and the level of

22

disease identified with the aid of noninvasive vascular examination complemented by computerized

23

tomography, magnetic resonance or invasive angiography. Based on this assessment, limbs with

24

occlusive disease and typical Rose claudication symptoms(19) were established as “claudicating

25

limbs” and selected for biomechanical analysis.

5
1

Control subjects were recruited from the community. Detailed history and physical

2

examination performed by vascular surgeons documented absence of PAD and co-morbidities as

3

described for PAD patients. Absence of PAD was confirmed by noninvasive testing (ankle-brachial

4

indexes) and absence of pain during ambulation. Each leg of these individuals was used as “control

5

limb”. To eliminate variability in gait due to shoes, all subjects wore the same standard laboratory

6

shoes (Cross Trekkers, Payless Shoes, Topeka, KS).

7

Lower extremity kinematics

8

Upon arrival in the laboratory, patients were prepared for data collection. Height, weight,

9

body mass index, age and anthropometric measurements were obtained. Reflective markers were

10

placed at specific anatomical locations of each subject’s lower limb utilizing the systems used by

11

Vaughan(20) and Nigg(21) and as described in Figure 1. The subjects’ lower extremity three-

12

dimensional kinematics was acquired with a high speed analog video Peak Performance system at

13

60Hz (Peak Performance Technologies, Englewood, CO). Marker identification was conducted

14

using the Peak Motus (Vicon-Peak Performance Technologies, Inc.) software. The exported marker

15

data was scaled and smoothed using a Butterworth low-pass filter with a selective cut-off algorithm

16

according to Jackson(22). The cut-off values used were 7-14 Hz. This analysis was performed using

17

custom software in Matlab (Mathworks Inc. Natick, Mass), where the exported data was also

18

converted to unit vectors for each local reference frame. Anthropometric measurements were

19

combined with three-dimensional marker data from the anatomical position calibration trial (see

20

below) to provide positions of the joint centers and define anatomical axes of joint rotations (20). The

21

positions of the reflective markers during the movement provided the three-dimensional joint angles

22

and were determined through triangulation of the position of the markers.

23

Prior to the walking trials, patients stood in the calibration device for five seconds while

24

kinematic video was collected with each leg in view of the cameras. The standing calibration trial

25

provided an anatomical reference position. The calculation of three-dimensional lower extremity

26

segment orientations and relevant joint angles was referred to this position. Kinematic data was

6
1

collected during the stance phase of walking (from heel contact to toe off). Initially five walking

2

trials were acquired from each PAD subject without pain present and represented the “pain free”

3

condition (PAD-PF). During this condition the patients were required to rest in a chair for at least

4

five minutes before, and between trials to ensure pain free measurements. After PAD patients

5

completed the pain free walking trials, claudication pain was induced. This was accomplished by

6

having patients walk on a treadmill at a 10% grade at 0.67 m/s until claudication was induced

7

(usually patients become symptomatic after 1 to 3 minutes on the treadmill) and then for

8

approximately 45 additional seconds. Patients returned to the walkway immediately where five

9

more walking trials were performed without any resting between the trials. Claudication pain was

10

present throughout these trials and represented the claudication or “pain” condition of the PAD

11

patients (PAD-P). Data from the healthy controls was collected following the protocol used to

12

obtain the pain free data from the PAD patients, with claudication data not obtained due to lack of

13

PAD in these individuals.

14

Data Analysis

15

Joint angles from the hip, knee and ankle were analyzed for the two conditions of the PAD

16

patients and for the controls. Dependent variables calculated were the range of motion, the

17

maximum and the minimum of the joints’ flexion and extension angles. All kinematic parameter

18

data files were normalized to 100 points for the stance phase using a cubic spline routine to enable

19

mean ensemble curves to be derived for each condition of each subject. All normalization occurred

20

after maximums and minimums were determined to ensure that the normalization did not distort

21

these values(23,24).

22

Statistical analysis

23

Statistical analysis was performed using SPSS (version 15; SPSS Inc, Chicago, Ili). Subject

24

and group means were calculated and inferential statistics were used to compare the different

25

groups. Independent t-tests were used to compare mean values of PAD patients (PAD-PF and PAD-

7
1

P) to healthy controls. Paired t-tests were used to compare PAD-PF to the PAD-P condition.

2

Significance was set at 0.05.

3
4

RESULTS

5

Demographics

6

Fourteen PAD patients (age: 58 +/- 3.4 years; weight: 80.99 +/- 15.64 kg; height: 172.12 +/-

7

6.78 cm) with clinically diagnosed femoro-popliteal occlusive disease (Ankle Brachial Index (ABI):

8

0.56 +/- 0.03, range 0.45-0.65) were recruited. All patients had classic Rose claudication or

9

Rutherford category 2 symptoms

(25)

. Eighty percent of the patients were hypertensive, 70% were

10

smokers, 60% had dyslipidemia, and 30% were obese (BMI>30 kg/m2). All patients were treatment

11

naive. From these fourteen patients, a total of 20 symptomatic PAD legs were included for

12

kinematic analysis. Five control subjects with absence of PAD and absence of any ambulatory

13

disability (age: 53 +/- 3.4 years; weight: 87.38 +/- 12.75 kg; height: 178.78 +/- 4.32 cm and ABI =

14

1.00 or greater) were evaluated. Two subjects had dyslipidemia and one had hypertension. From

15

these subjects both legs were utilized providing a total of 10 legs. Body mass index values were

16

28.5 +/- 0.98 for PAD patients and 27.3 +/- 1.5 for control subjects. Subjects were well-matched

17

regarding age and body mass index with no significant differences noted between groups (p <

18

0.05).

19

Kinematic Analysis

20

At the level of the ankle, significant differences were noted between PAD patients and

21

control subjects (Table 1). Increased minimum (negative values) ankle plantar flexion during the

22

initial stance phase and increased range of motion (ROM) throughout the stance phase was

23

observed in claudicants when compared to controls in both PAD-PF and PAD-P conditions (Table

24

1; Figure 2). Since no differences were found for maximum (positive values) ankle dorsiflexion

25

(Table 1), these results are reflected as a deeper “valley” on the ankle mean ensemble curve for

26

PAD patients when compared with the control subjects (Figure 2). The time to minimum plantar

8
1

flexion and maximal dorsiflexion of the ankle joint during the stance phase was significantly altered

2

when comparing PAD-P to control subjects. The PAD-P patient reached minimum ankle plantar

3

flexion faster and maximum dorsiflexion later than the control subject (Table 2). When analyzing

4

the effect of claudication on joint motion at the knee and hip, no significant differences were noted

5

in joint angles.

6

When analyzing the effect of claudication pain by comparing the PAD-PF to PAD-P

7

conditions, there were no significant differences noted in joint motion at each joint level or in the

8

timing of specific points within the gait cycle. These results are also reflected in the mean ensemble

9

curves since the lines for PAD-P and PAD-PF are overlapping throughout stance (Figure 2).

10
11

DISCUSSION

12

Our data demonstrated that patients with clinically diagnosed femoro-popliteal PAD have

13

significant ankle motion alterations with abnormal ankle joint kinematics. During the stance phase

14

of the gait cycle, the PAD patients demonstrated rapid foot plantar flexion after initial heel strike

15

coupled with a significant increase in ankle plantar flexion. The increase in ankle plantar flexion

16

with subsequent normal maximal dorsiflexion resulted in PAD patients having a significantly

17

increased ankle range of motion. This phenomenon was present both before and after the onset of

18

claudication pain. Based on our kinematic analysis, PAD patients have what appears to be “foot

19

drop” upon heel touchdown. The etiology of this finding is currently unknown but is likely

20

secondary to nerve damage and muscle weakness from chronic ischemia

21

in poor eccentric motor control from the foot dorsiflexors (anterior and lateral compartment leg

22

muscles) in combination with suboptimal plantar flexor function (posterior compartment muscles).

23

Taken together, these findings represent either a compensatory mechanism to maintain stability due

24

to inherent neuromuscular weakness of the lower limb or alternatively an adaptation to altered

25

neuromuscular function due to PAD. Consistent with any dysfunctional gait, PAD patients have a

26

deviation from normal walking parameters that results in an increased work requirement and energy

(28,29,33)

. This could result

9
1

cost. (39,40). Future research should expand on the analysis of joint moments at the level of the ankle

2

to confirm the location of motor dysfunction and the contribution of nerve dysfunction to the gait

3

abnormality.

4

In contrast to the findings at the ankle in our current cohort of patients, there was a lack of

5

changes in the hip and knee in both flexion and extension in both conditions for PAD and control

6

patients. This result could be due to the fact that the patients in the current study had clinically

7

diagnosed femoro-popliteal occlusive disease with classic Rose claudication with absence of thigh

8

and buttock claudication. One could argue that only the lower leg musculature was involved in the

9

ischemic process and therefore the proximal muscles were spared. Further studies will be necessary

10

to delineate the full spectrum of ambulatory compromise in patients with isolated aorto-iliac

11

occlusive disease and multi-level disease.

12

An important finding in our study is that PAD patients had evidence of significant

13

ambulatory abnormalities even when not experiencing any claudication pain. There is likely also a

14

further alteration in gait function with claudication pain as the patients in our series showed a trend

15

for increased differences of gait parameters compared to controls such as ankle plantar flexion and

16

range of motion after onset of claudication pain but the differences did not reach statistical

17

significance.. These results confirm unequivocally the presence of a significantly altered and

18

dysfunctional gait prior to the onset of claudication pain despite what appears to be “normal” gait

19

by simple visual analysis. These findings we believe reflect a baseline lower extremity dysfunction

20

in PAD patients with origins at the cellular level(26,27). The abnormalities contributing to the

21

baseline gait dysfunction include axonal nerve loss

22

of which could account for the underlying gait dysfunction found in PAD patients from the first

23

step during ambulation. Ischemia superimposed on underlying neuromuscular dysfunction would

24

then result in variably worsening gait as seen in our previous kinetic analysis (18).

(28,29)

and mitochondrial dysfunction(30-35) both

25

Previous studies have reported kinematic analysis of elderly individuals, showing deceased

26

ankle plantar flexion when compared with younger controls(36). The results of the kinematic analysis

10
1

of our control patients are similar to those reported on the literature on healthy elderly subjects. In

2

contrast, little data exists to document the kinematic analysis of patients with PAD. Previous

3

literature utilized simple visual observations in PAD patients to analyze differences in gait

4

parameters with conflicting results. A recent study by Crowther et al has documented the effect of

5

PAD on gait biomechanical parameters, only before the onset of claudication pain(17). Although

6

difficult to compare to our study due to differing methodologies, this study also found differences at

7

the ankle. In contrast to our results, they found differences in the knee ROM and hip extension. Our

8

methodology only included patients with clinically diagnosed femoro-popliteal disease and focused

9

the analysis of the joints to the stance phase of the gait cycle. Crowther et al did not specify a level

10

of disease among the patients and included the swing phase in the analysis of the joints’ ranges of

11

motion. Another factor contributing to the precision of our results is the capability of our lab to

12

provide a three-dimensional analysis given the number of cameras used, Crowther et al, in contrast,

13

utilized a two-dimensional kinematic analysis of the sagittal plane, which is vulnerable to

14

perspective error

15

demonstrated an increased plantar flexion in the control patients in the swing phase only. Our

16

results, similar to Crowther et al, showed increased plantar flexion of the controls at the end of

17

stance phase. In contrast to Crowther’s report, we detected an increased plantar flexion of the PAD

18

patients in the stance phase. Both studies document similar alterations at the ankle level with the

19

differences secondary to methodology and length of gait cycle analyzed. Both studies confirm

20

however the significant ankle dysfunction in the PAD patient and providing a start point to

21

elucidate the underlying joint biomechanical abnormalities found in patients with symptomatic

22

PAD.

(37,38)

. When comparing the ankle curves of both studies, Crowther et al

23
24

CONCLUSION

25

Kinematic gait analysis demonstrates that patients with clinically diagnosed femoropopliteal

26

disease have altered ankle plantar flexion present before and after the onset of claudication pain

11
1

compared to control subjects. Our data in conjunction with previous biomechanical analysis

2

confirm that patients with symptomatic PAD have an underlying ambulatory abnormality present

3

even prior to onset of claudication pain. Further biomechanical evaluation of PAD patients should

4

focus on the impact of disease level on gait dysfunction and evaluation of joint moments and

5

powers to identify the specific muscular deficits produced by PAD. Our results provide evidence for

6

the utilization of advanced biomechanical analysis to identify the unique gait abnormalities in PAD

7

patients, thus providing a powerful research tool for objective analysis of medical and surgical PAD

8

treatment and rehabilitation therapy.

9
10
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Table 1

Control (degrees)

PAD-PF (degrees)

p†

PAD-P (degrees)

p‡

p

Hip Flex

22.824±3.334

23.094±4.751

NS

22.9388±5.009

NS

NS

Hip Ext

-20.225±3.605

-18.773±6.427

NS

-19.1206±5.390

NS

NS

Hip ROM

43.050±1.915

41.870±6.542

NS

42.060±5.846

NS

NS

Knee Flex

19.021±4.849

18.065±6.261

NS

17.525±6.741

NS

NS

Knee Ext

1.247±4.246

1.102±5.504

NS

0.842±5.677

NS

NS

Knee ROM

17.773±3.649

16.962±5.493

NS

16.684±4.688

NS

NS

Ankle Plantarflex

-3.458±3.427

-7.596±2.520

0.0001

-8.368±2.764

0.0004

NS

Ankle Dorsiflex

14.500±2.407

16.539±4.767

NS

16.254±4.470

NS

NS

Ankle ROM

17.962±4.531

24.1371±4.934

0.003

24.621±4.363

0.001

NS

Table 2

Control (degrees)

PAD-PF (degrees)

p†

PAD-P (degrees)

p‡

p

Hip Flex time

13.919±6.761

13.523±7.627

NS

12.209±5.801

NS

NS

Hip Ext time

86.439±1.349

86.180±3.292

NS

87.241±2.244

NS

NS

Knee Flext time

28.447±3.783

26.838±6.065

NS

26.851±6.383

NS

NS

Knee Ext time

68.87±1.949

68.268±5.186

NS

67.296±5.960

NS

NS

Ankle Plantarflex time

17.087±1.800

16.224±2.526

NS

15.710±1.233

0.026

NS

Ankle Dorsiflex time

72.788±11.327

78.264±7.134

NS

79.966±5.815

0.038

NS
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Figure/Table Legend

Figure 1: Anatomic location of markers in lower extremities. The position and
trajectories of these markers were captured by our cameras. The analysis and process of
this data originates curves corresponding to relative joint angles during stance time of the
selected limb.

Figure 2. Average curves for hip, knee and ankle joints representing healthy control
patients and PAD-PF and PAD-P conditions.

Table 1. Group means of joint angle parameters in controls and PAD patients both before
and after the onset of claudication.
PAD-PF, pain free condition PAD patient; PAD-P, pain condition PAD patient; NS
statistically non significant; ROM, range of motion
†

Control vs. PAD-PF

‡

Control vs. PAD-P



PAD-PF vs. PAD-P

Table 2: Group means of time to maximal flexion and extension of the joints in controls
and PAD patients both before and after the onset of claudication.
PAD-PF, pain free PAD patient; PAD-P, pain condition PAD patient; NS statistically non
significant; ROM, range of motion
†

Control vs. PAD-PF

‡

Control vs. PAD-P



PAD-PF vs. PAD-P

